Skip to main content
SpringerLink
Log in

Industry Pulse

Editorial Development by Adis International Limited, Italy

  • Industry Pulse
  • Published:
High Blood Pressure & Cardiovascular Prevention Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II

References

  1. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The LIFE Study Group. Lancet 2002 Mar 23; 359(9311): 995–1003

    Article  PubMed  CAS  Google Scholar 

  2. Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention For Endpoint Reduction (LIFE) substudy. The LIFE Study Group. JAMA 2002 Sep 25; 288(12): 1491–8

    Article  PubMed  CAS  Google Scholar 

  3. The Heart Outcome Prevention Evaluation Study investigators. Effects of an angiotensin-converting-enzyme inhibitor ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53

    Google Scholar 

  4. Ibsen H, Wachtell K, Olsen MH, et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004 Sep; 22(9): 1805–11

    Article  PubMed  CAS  Google Scholar 

  5. Bendall JK, Cave AC, Heymes C, et al. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 2002 Jan 22; 105(3): 293–6

    Article  PubMed  CAS  Google Scholar 

  6. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes: the HOPE study investigators. J Am Med Assoc 2001; 286: 1882–5

    Article  CAS  Google Scholar 

  7. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–50

    Article  PubMed  CAS  Google Scholar 

  8. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin: the Diabetes Prevention Program Research Group. N Engl J Med 2002; 346: 393–403

    Article  PubMed  CAS  Google Scholar 

  9. Damas J, Bourdon V, Lefèbvre PJ. Insulin sensitivity, clearance and release in kininogen-deficient rats. Exp Physiol 1999; 84: 549–57

    Article  PubMed  CAS  Google Scholar 

  10. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–421

    Google Scholar 

  11. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326): 7–22

    Google Scholar 

  12. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. PROspective Study of Pravastatin in the Elderly at Risk: the PROSPER study group. Lancet 2002; 360: 1623–30

    Article  PubMed  CAS  Google Scholar 

  13. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998–3007

    Google Scholar 

  14. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58

    Article  PubMed  CAS  Google Scholar 

  15. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes: Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 investigators. N Engl J Med 2004; 350: 1495–504

    Article  PubMed  CAS  Google Scholar 

  16. Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines: the Coordinating Committee of the National Cholesterol Education Program, endorsed by the National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, and American Heart Association. Circulation 2004; 110: 227–39

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Industry Pulse. High Blood Press Cardiovasc Prev 12, 53–56 (2005). https://doi.org/10.2165/00151642-200512010-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151642-200512010-00008

Search

Navigation